Loading…
Myomo, Inc. is projected to rise to $1.20 by 2027, a +20% move from its current price of $1.00. MYO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.9571 | $0.9997 | $1.04 | -0.03% |
| May 30 | $0.9397 | $0.9994 | $1.06 | -0.06% |
| May 31 | $0.9265 | $0.999 | $1.08 | -0.10% |
| Jun 1 | $0.9155 | $0.9987 | $1.09 | -0.13% |
| Jun 2 | $0.9058 | $0.9984 | $1.10 | -0.16% |
| Jun 3 | $0.8971 | $0.9981 | $1.11 | -0.19% |
| Jun 4 | $0.8892 | $0.9978 | $1.12 | -0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8892 | $0.9978 | $1.12 | -0.22% |
| Week 2 | $0.8459 | $0.9955 | $1.17 | -0.45% |
| Week 3 | $0.8137 | $0.9933 | $1.21 | -0.67% |
| Week 4 | $0.7872 | $0.9911 | $1.25 | -0.89% |
| Week 5 | $0.7644 | $0.9889 | $1.28 | -1.11% |
| Week 6 | $0.7442 | $0.9867 | $1.31 | -1.33% |
| Week 7 | $0.7259 | $0.9845 | $1.34 | -1.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library.
In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran's administration, and distributors.
Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
Myomo, Inc. (MYO) is a healthcare stock with a current price of $1.04 and a market capitalization of $40.18M. It is ranked 4690 by market position. The stock’s outlook, based on year-by-year forecasts, shows modest upside beginning in the late 2020s and accelerating into the 2030s and beyond.
The forecasted path includes a 2026 average near the current price and higher averages in later years, with substantial potential upside by 2040 and 2050, reaching an average price of $5.01 by 2050 and a maximum forecast around $11.52. These numbers reflect notable long-run upside despite near-term variability.
A major floor 36.0% below — a decisive break under it would weaken the trend.
The nearest floor, 22.2% below — buyers have tended to step in here.
The nearest ceiling, 4.0% above — a clean break opens room to run.
A major ceiling 20.1% above — clearing it would confirm fresh momentum.
Key MYO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MYO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.987 | Buy | $0.9842 | Buy |
| MA 10 | $0.9263 | Buy | $0.9446 | Buy |
| MA 20 | $0.8868 | Buy | $0.8992 | Buy |
| MA 50 | $0.7992 | Buy | $0.8441 | Buy |
| MA 100 | $0.8228 | Buy | $0.8803 | Buy |
| MA 200 | $0.9002 | Buy | $1.24 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.17 | Neutral |
| Stoch RSI (14) | 76.54 | Neutral |
| CCI (20) | 140.12 | Buy |
| Williams %R (14) | -15.27 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 20.77 | Buy |
| Bollinger %B (20,2) | 0.90 | Neutral |
| Stochastic %K (14) | 84.73 | Sell |
| TRIX (15) | 0.66 | Buy |
| Awesome (5,34) | 0.14 | Buy |
| Ultimate (7,14,28) | 63.05 | Neutral |
| Momentum (10) | 0.22 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 1.05 | Sell |
| ADX (14) | 17.13 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture shows bullish sentiment with RSI14 at 70, indicating strong momentum near overbought levels. The stock trades above the SMA50 of $0.7873 and the SMA200 of $0.9081, suggesting a solid intermediate-term setup. The 30-day range runs from $0.7687 to $1.41, with a current resistance at $1.04 and support at $0.73.
Annualized volatility sits at 90%, underscoring elevated price swings over short horizons.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.64 | $1.00 | $1.40 | 0% | Neutral | |
| $0.8984 | $1.20 | $1.73 | +20% | Bullish | |
| $0.8093 | $1.13 | $1.72 | +13% | Neutral | |
| $0.809 | $1.18 | $1.86 | +18% | Neutral | |
| $0.7806 | $1.18 | $1.93 | +18% | Neutral | |
| $0.7716 | $1.20 | $2.03 | +20% | Bullish | |
| $0.991 | $1.60 | $2.76 | +60% | Bullish | |
| $1.06 | $1.77 | $3.13 | +77% | Bullish | |
| $1.13 | $1.93 | $3.49 | +93% | Bullish | |
| $1.22 | $2.15 | $3.97 | +115% | Bullish | |
| $1.54 | $3.08 | $6.18 | +208% | Bullish | |
| $2.05 | $4.56 | $10.30 | +356% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.64 | $1.00 | $1.18 | +0.00% |
| June 2026 | $0.8138 | $0.9682 | $1.19 | -3.18% |
| July 2026 | $0.8054 | $0.9713 | $1.22 | +0.32% |
| August 2026 | $0.8266 | $1.01 | $1.28 | +3.74% |
| September 2026 | $0.8029 | $0.9875 | $1.27 | -2.00% |
| October 2026 | $0.7744 | $0.9603 | $1.25 | -2.76% |
| November 2026 | $0.8063 | $1.01 | $1.33 | +4.88% |
| December 2026 | $0.8363 | $1.05 | $1.40 | +4.44% |
Click any year to see its month-by-month MYO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MYO is projected to trade between $0.64 and $1.40, averaging $1.00 — a potential gain of 0% from today's $1.00. Price action looks broadly range-bound.
Myomo, Inc.'s 2027 outlook centres on $1.20, within a $0.8984 to $1.73 range. That is up +20% on the projected 2026 average. That marks a +20% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, MYO could reach as high as $1.72, with a base case around $1.13 and support toward $0.8093 — roughly +13% from $1.00. Price action looks broadly range-bound.
Expect MYO to range from $0.809 to $1.86 through 2029. The $1.18 average target implies a +18% move from current prices. That is up +4% on the projected 2028 average. A consolidation phase looks the most probable path here.
The MYO price prediction for 2030 points to an average of $1.18 (low $0.7806, high $1.93) — a potential gain of +18% on today's $1.00. Price action looks broadly range-bound.
In 2031, MYO is projected to trade between $0.7716 and $2.03, averaging $1.20 — a potential gain of +20% from today's $1.00. That is up +2% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Myomo, Inc.'s 2032 outlook centres on $1.60, within a $0.991 to $2.76 range. That is up +33% on the projected 2031 average. That marks a +60% change versus current levels. Momentum favours further upside here.
By 2033, MYO could reach as high as $3.13, with a base case around $1.77 and support toward $1.06 — roughly +77% from $1.00. Buyers look set to stay in control over this stretch.
Expect MYO to range from $1.13 to $3.49 through 2034. The $1.93 average target implies a +93% move from current prices. That is up +9% on the projected 2033 average. Momentum favours further upside here.
The MYO price prediction for 2035 points to an average of $2.15 (low $1.22, high $3.97) — a potential gain of +115% on today's $1.00. Buyers look set to stay in control over this stretch.
In 2040, MYO is projected to trade between $1.54 and $6.18, averaging $3.08 — a potential gain of +208% from today's $1.00. That is up +43% on the projected 2035 average. Momentum favours further upside here.
Myomo, Inc.'s 2050 outlook centres on $4.56, within a $2.05 to $10.30 range. That is up +48% on the projected 2040 average. That marks a +356% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in MYO today (≈ 1,000 MYO) could be worth
$4,555.32
+$3,555.32 (+356%) by 2050 · US Dollar
Based on the average projected MYO price of $4.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MYOwould be worth at today's price.
$1,000 invested in MYO on May 27, 2025 (≈ 318.471327 MYO) would be worth
$318.47
-$681.53 (-68.2%) today · 0.32× · US Dollar
Based on a MYO entry price of $3.14 vs. today's $1.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.915 | $1,092.9 | +9.3% |
| 1 month ago | $0.831 | $1,203.37 | +20.3% |
| 3 months ago | $0.784 | $1,275.51 | +27.6% |
| 6 months ago | $0.89 | $1,123.6 | +12.4% |
| 1 year ago | $3.14 | $318.47 | -68.2% |
| All time (5.0y) ago | $10.78 | $92.76 | -90.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MYO forecast.
Our base-case forecast reaches $2.00 around 2035.
Implied market cap at $2.00: $77.28M
The multi-year forecast paints an upward trajectory. For 2026, the min is $0.64, the avg is $1.04, the max is $1.47, with ROI 0 and a Neutral sentiment. In 2027, the min is $0.9266, the avg is $1.25, the max is $1.82, ROI 20.3, and a Bullish sentiment.
The forecast continues to rise through 2030 with an avg of $1.24 and ROI of 19.3%. By 2032 the min is $1.05, the avg $1.73, the max $3.04, ROI 66, and a Bullish sentiment. The 2033–2035 period shows further upside (2033: min $1.13, avg $1.92, max $3.47, ROI 84.6; 2034: min $1.21, avg $2.11, max $3.90, ROI 103.3; 2035: min $1.29, avg $2.33, max $4.39, ROI 124.1) with bullish momentum.
In 2040, the min is $1.65, the avg $3.44, the max $7.06, ROI 230.8, and sentiment Bullish. The long-run view culminates in 2050 with min $2.25, avg $5.01, max $11.52, ROI 381.4, and a Bullish sentiment. These figures imply meaningful upside over the coming years, tempered by near-term variability and execution risks inherent in small-cap healthcare equities.
Tap a question to reveal the answer.
2030 min $0.8073, avg $1.24, max $2.06, ROI 19.3%, sentiment Neutral.
The forecast shows a Neutral stance in 2026, then Bullish in 2027 and again in later years, with rising averages and ROIs (e.g., 2027 avg $1.25, ROI 20.3%; 2032 avg $1.73, ROI 66%; 2040 avg $3.44, ROI 230.8%; 2050 avg $5.01, ROI 381.4%). These are estimates and not guarantees.
The 2050 max forecast is $11.52, indicating a possibility of reaching or exceeding $10 within the forecast horizon.
The current price is $1.04.
2040 min $1.65, avg $3.44, max $7.06, ROI 230.8, sentiment Bullish.
Myomo, Inc. Community Discussion
0Share your Myomo, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.